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study
Clive J. Petry1* , Ken K. Ong1,2,3, Kathryn Beardsall1, Ieuan A. Hughes1, Carlo L. Acerini1 and David B. Dunger1,3
Abstract
Background: Low birth weight has important short- and long-term health implications. Previously it has been
shown that pregnancies affected by hyperemesis gravidarum in the mother are at higher risk of having low birth
weight offspring. In this study we tested whether such risks are also evident with less severe nausea and vomiting
in pregnancy.
Methods: One thousand two hundred thirty-eight women in the prospective Cambridge Baby Growth Study filled
in pregnancy questionnaires which included questions relating to adverse effects of pregnancy and drugs taken
during that time. Ordinal logistic regression models, adjusted for parity, ethnicity, marital and smoking status were
used to relate the risk of giving birth to low birth weight (< 2.5 kg) babies to nausea and/or vomiting in pregnancy
that were not treated with anti-emetics and did not report suffering from hyperemesis gravidarum.
Results: Only three women in the cohort reported having had hyperemesis gravidarum although a further 17
women reported taking anti-emetics during pregnancy. Of those 1218 women who did not take anti-emetics 286
(23.5%) did not experience nausea or vomiting, 467 (38.3%) experienced nausea but not vomiting and 465
experienced vomiting (38.2%). Vomiting during pregnancy was associated with higher risk of having a low birth
weight baby (odds ratio 3.5 (1.2, 10.8), p = 0.03). The risk associated with vomiting was found in the first (p = 0.01)
and second (p = 0.01) trimesters but not the third (p = 1.0). The higher risk was not evident in those women who
only experienced nausea (odds ratio 1.0 (0.3, 4.0), p = 1.0).
Conclusions: Vomiting in early pregnancy, even when not perceived to be sufficiently severe to merit treatment, is
associated with a higher risk of delivering a low birth weight baby. Early pregnancy vomiting might therefore be
usable as a marker of higher risk of low birth weight in pregnancy. This may be of benefit in situations where
routine ultrasound is not available to distinguish prematurity from fetal growth restriction, so low birth weight is
used as an alternative.
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Background
Low birth weight (LBW) leads to a higher risk of peri-
natal mortality and morbidity, including impaired
growth and cognitive development [1]. More long-term
complications include higher risks for high blood pres-
sure [2] and cardiovascular disease [3], impaired glucose
tolerance and type 2 diabetes [4], early age at menarche
[5] and menopause [6], and reduced bone mineral dens-
ity [7] and osteoporosis [8]. LBW can relate to one or
both of premature birth and fetal growth restriction, or
being constitutionally small, and risk of LBW can be re-
lated to such factors as ethnic differences, multiple birth
pregnancies, maternal age at birth, fetal environmental
factors such as exposure to alcohol, smoking or illicit
drugs, maternal nutrition during pregnancy, poor socio-
economic status [9] and genetic defects [10]. Another risk
factor appears to be hyperemesis gravidarum [11–13], a
severe form of nausea and vomiting in pregnancy that can
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lead to maternal dehydration and weight loss. Treatment
of severe nausea and vomiting in pregnancy with anti-
emetics may even be associated with a reduction in the
prevalence of LBW [14, 15], although such findings are by
no means universal [16–18].
Whilst the association between hyperemesis gravi-
darum and higher risk of LBW is reasonably well estab-
lished, what is not so clear is whether potentially less
severe nausea and/or vomiting in pregnancy is also asso-
ciated with the risk of delivering LBW babies. The only
recent related evidence suggests that it may be associ-
ated with being small for gestational age (SGA) due to
fetal growth restriction, one of the main reasons for a
baby having a LBW [19]. This study was therefore de-
signed to test the hypothesis that nausea and vomiting
in pregnancy, of insufficient severity to require treat-
ment, is associated with the risk of delivering a LBW
baby. To do this we used data collected for the Cam-
bridge Baby Growth Study.
Methods
Cohort
The prospective and longitudinal Cambridge Baby
Growth Study recruited 2229 mothers (and their part-
ners and offspring) attending ultrasound clinics during
early pregnancy at the Rosie Maternity Hospital,
Cambridge, United Kingdom, between 2001 and 2009
[20]. All mothers were over 16 years of age. Birth
weights of their babies, their sex and their gestational
age at birth were extracted from hospital notes, having
been recorded there by midwives. LBW was defined as a
birth weight of less than 2.5 kg. SGA was classified as
being in the lowest tenth percentile for gestational age.
Prematurity was defined as being born prior to week 37
of gestation. Categorisation according to whether or not
the participants developed gestational diabetes [21] or
gestational hypertension [22] has been described previ-
ously. In this cohort, 96.9% of the offspring were of
white ethnicity, 0.8% were of mixed race, 0.6% were
black (African or Caribbean), 0.8% were East-Asian, and
0.9% were Indo-Asian.
Each of the study participants was given a printed
questionnaire at recruitment with questions to answer
and return once the pregnancy was completed [23].
They were encouraged to fill it in as the pregnancy pro-
gressed. The questionnaires included boxes to tick if the
participants had experienced nausea or had vomited
during pregnancy. If either of these boxes were ticked
there were further boxes to fill in concerning the timing
(i.e. week(s) of pregnancy) when the nausea or vomiting
were experienced. A further question asked “Have you
taken any medicine during this pregnancy?” Those
women who responded in the affirmative were then
asked to complete a table with the following headings:
“Name”, “Disease”, “Daily Dose”, “No. of Days” and
“Gestational Week(s)”. This means that nausea and
vomiting prior to attending the booking clinic would
have had to have been recalled over a maximum period
of several weeks whereas nausea and vomiting subse-
quent to that could be recorded as the pregnancy pro-
gressed (requiring recollection over a much shorter
period of time). A total of 1238 women (54.6%) filled in
the questionnaires; those that did not were excluded
from the present analysis. For 598 of the pregnancies
where the mother failed to return a filled-in question-
naire the baby’s birth weight was also missing. The birth
weights of the remaining babies, adjusted for pre-
pregnancy maternal BMI, gestational age at birth, parity
and sex, were not different between those that com-
pleted the questionnaire and those that did not (filled in
questionnaire 3.482 (3.456, 3.508) kg v. did not fill in
questionnaire 3.403 (3.310, 3.497) kg, p = 0.1), although
the prevalence of LBW in the offspring of the women
that returned the questionnaires was lower (filled in
questionnaire 37/1218 v. did not fill in questionnaire
27/431, p = 5 × 10− 3). Of those women that filled in
their questionnaires only 3 reported that they had
hyperemesis gravidarum and a further 17 were treated
with anti-emetics: cyclizine (7), promethazine (5), pro-
chlorperazine (4), metoclopramide (2), domperidone
(2), prednisolone (2), chlorphenamine (1), ondanse-
tron (1), chlorpromazine (1) and unknown (1). These
20 women were excluded from this specific analysis
in order to test only those women who had a poten-
tially milder phenotype. The self-reported timings of
exposure to nausea and/or vomiting were divided into
trimesters (first trimester being up to gestational week
12, second trimester being weeks 13 to 27 and third
trimester being from week 28 onwards).
Categorisation and calculations
We categorised each of the women into one of three dif-
ferent groups: those who reported neither nausea nor
vomiting (n = 286), those who reported nausea but not
vomiting (n = 467) and those who reported vomiting
(n = 465, 432 of whom reported nausea and vomiting
and 33 who reported vomiting without nausea). Those
that reported vomiting without nausea had no evidence
of concurrent urinary or chest infections, or evidence of
the vomiting occurring just in the final trimester of
pregnancy. The body mass indexes (BMI) were calcu-
lated dividing the maternal weights prior to pregnancy
by their heights squared.
Statistical analysis
Associations with LBW were adjusted for the following
confounders: parity, marital and smoking statuses, and
ethnicity [24]. Associations between nausea and vomiting
Petry et al. BMC Pregnancy and Childbirth  (2018) 18:133 Page 2 of 8
and quantitative continuous variables (such as BMI and
maternal age) were tested using linear regression models
(adjusted for confounders where necessary). Associations
with dichotomous variables (such as LBW) were tested
using ordinal logistic regression (adjusted for confounders
where necessary), the χ2-test or Fisher’s exact test as
appropriate. Unless otherwise stated all other data are
presented as means (95% confidence intervals (CI)).
Statistical analyses were performed using Stata 13
(StataCorp LP, College Station, Texas, U.S.A.). P < 0.05
was considered statistically significant throughout.
Results
Maternal clinical characteristics
Table 1 shows the clinical characteristics of the different
groups tested. Those 465 women who experienced
vomiting during pregnancy (432 of whom also reported
nausea) tended to be younger (p = 1.5 × 10− 3) and
slightly heavier/more obese (pre-pregnancy weight p = 0.02,
pre-pregnancy BMI p = 0.01) than those women who did
not experience nausea or vomiting in pregnancy. These dif-
ferences in clinical characteristics from those women who
did not experience nausea or vomiting, were not evident in
those women who experienced nausea but not vomiting.
Associations between maternal exposure to nausea and/
or vomiting in pregnancy and birth characteristics of the
baby
The delivery of LBW babies was more common in those
women who experienced vomiting in pregnancy (when
adjusted for confounders) than in those women who did
not experience vomiting or nausea (p = 0.03; Table 2).
This relationship was still evident after further adjustment
was made for maternal BMI prior to pregnancy (OR 3.1
(1.0, 9.7), p = 0.048). In contrast there was no higher risk
of LBW associated with experiencing nausea but not
vomiting in pregnancy (p = 1.0).
Table 2 shows other birth characteristics of women ac-
cording to their experience of nausea and vomiting in
pregnancy. Despite the differences in risk of LBW, there
was no apparent difference in mean birth weight, gesta-
tional age at birth or prevalence of prematurity or SGA.
Similarly there was no apparent difference in the birth
weight adjusted for pre-pregnancy maternal BMI, gesta-
tional age at birth, sex and parity. However there was a
slightly higher proportion of female babies born to
mothers who experienced vomiting during pregnancy.
Figure 1 shows Kernel density estimation plots for un-
adjusted birth weight, gestational age at birth and birth
weight for gestational age according to maternal expos-
ure to nausea and vomiting in pregnancy. Small differ-
ences in the distributions of these were evident in each
plot.
Associations between exposure to vomiting in different
trimesters of pregnancy and birth characteristics of the
baby
The higher prevalence of giving birth to LBW babies in
women who experienced vomiting was evident in those
who experienced it in the first (OR 4.3 (1.4, 13.2), p = 0.01,
n = 266 vomiting and n = 204 no nausea or vomiting) or
second (OR 4.4 (1.4, 13.9), p = 0.01, n = 185 vomiting and
n = 204 no nausea or vomiting) trimester of pregnancy.
However it was not evident in those who experienced it in
the third trimester (OR 1.0 (1.0, 1.0), n = 36 vomiting and
204 no nausea or vomiting, p = 1.0).
Table 1 Characteristics of the pregnant women in the Cambridge Baby Growth Study who returned their questionnaires
categorised according to whether or not they experienced nausea or vomiting in pregnancy
Characteristic No Nausea or Vomiting Nausea alone Vomiting
n 286 467 465
Age (years) 34.2
(33.7, 34.6)
33.6
(33.4, 33.9)
33.1***
(32.7, 33.4)
Height (m) 166.1
(165.3, 166.8)
165.9
(165.5, 166.3)
165.7
(165.1, 166.4)
Pre-pregnancy weight (kg) 65.0
(63.6, 66.4)
66.1
(65.3, 66.9)
67.1*
(66.0, 68.3)
Pre-pregnancy BMI (kg/m2) 23.6
(23.1, 24.1)
24.0
(23.7, 24.3)
24.5*
(24.0, 24.9)
Weight gain during pregnancy (kg) 7.9
(7.1, 8.7)
8.2
(7.7, 8.6)
8.4
(7.7, 9.1)
Smoked during pregnancy (%) 4.2 1.9 4.6
Developed gestational diabetes (%) 10.6 9.6 9.6
Developed gestational hypertension (%) 6.9 4.2 7.2
*P < 0.05, **P < 0.01, ***P < 0.001 compared with the no nausea or vomiting group. Data are mean (95% CI). None of these women were treated with anti-emetics
during pregnancy. Nausea alone refers to those women who experienced nausea in pregnancy but not vomiting. Vomiting refers to those women who experienced
vomiting during pregnancy, independently of whether or not they also experienced nausea
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Discussion
Vomiting in pregnancy, not treated with anti-emetics, is
associated with a higher risk of giving birth to LBW ba-
bies in this study. This is consistent with reported asso-
ciations between LBW (or related phenotypes such as
SGA) and hyperemesis gravidarum [11–13, 25–28], al-
though such associations are not universal findings
[29–32]. Nausea and vomiting with no reference to
hyperemesis gravidarum has also been associated with
a higher risk of LBW [33] and decreased birth weight
[34] in some other studies, although no difference in
risk was reported in others [19, 35–37]. Although a
systematic review [38] reported a lower risk of LBW
in association with nausea and vomiting in pregnancy
the studies that it was based looked at anti-emetic
use to categories study participants [14, 15]. This is
therefore very different to our own study where we
specifically excluded women who took anti-emetics in
case these drugs affected pathways involved in regu-
lating LBW risk [39]. Similarly the very large Norwe-
gian Mother and Child Cohort Study [40] found
reduced population rates of LBW in association with
nausea and vomiting in pregnancy, but did so without
specifically excluding those women who took anti-
emetics in pregnancy. Our study therefore presents
results a slightly different population to those exam-
ined in other investigations, and one where we specif-
ically investigated a potentially milder negative aspect
of pregnancy than hyperemesis gravidarum.
This higher risk for LBW associated with vomiting,
and nausea but just in the second trimester, appeared to
be in the first two trimesters of pregnancy with an ap-
parent lack of risk in the third trimester. Studies are on-
going to try and discover whether or not nausea and
vomiting in pregnancy and resulting associations are
genetically mediated [41, 42]. With an overall odds ratio
of 3.5 for LBW in our population, vomiting in early
pregnancy may be a marker of risk for LBW that is use-
ful for its prediction in conjunction with other risk fac-
tors. Where routine ultrasound is available small babies
tend to be assessed as either SGA (possibly due to fetal
growth restriction) and/or premature rather than LBW,
but the link with vomiting may be useful in areas where
such scans are not available and LBW is used to
Table 2 Birth related factors of babies of women in the Cambridge Baby Growth Study who returned their questionnaires,
categorised according to whether they experienced nausea or vomiting in pregnancy
Birth-related Factor No Nausea or Vomiting Nausea alone Vomiting
n 286 467 465
Parity (n) 1.7
(1.6-1.8)
1.8
(1.7-1.8)
1.8*
(1.8-1.9)
Birth weight (kg) 3.512
(3.459, 3.565)
3.504
(3.474, 3.534)
3.496
(3.453, 3.540)
Adjusted birth weight (kg) 3.494
(3.449, 3.539)
3.499
(3.474, 3.525)
3.505
(3.468, 3.541)
LBW (n/total (%)) 6/277
(2.2%)
9/461
(2.0%)
21/460*
(4.6%)
LBW (OR) Ref. 1.0
(0.3-4.0)
3.5*
(1.2-10.8)
LBW (OR) first trimester nausea or vomiting 2.1
(0.8-5.7)
4.3*
(1.4-13.2)
LBW (OR) second trimester nausea or vomiting 4.2*
(1.7-10.1)
4.4*
(1.4-13.9)
LBW (OR) third trimester nausea or vomiting 1.5
(0.3-6.7)
0.8
(0.1-7.0)
Gestational age at birth (weeks) 39.9
(39.8, 40.1)
39.9
(39.8, 40.0)
39.8
(39.7, 39.9)
Prematurity
(n (%))
4
(1.4)
7
(1.5)
11
(2.3)
SGA
(n (%))
11
(3.9)
16
(3.5)
25
(5.2)
Sex of the baby
(n (%) male)
161
(56.9%)
236
(51.1%)
225
(49.9%)*
*P < 0.05, **P < 0.01, ***P < 0.001 compared with the no nausea or vomiting group. None of these women were treated with anti-emetics during pregnancy.
Nausea alone refers to those women who experienced nausea in pregnancy but not vomiting. Vomiting refers to those women who experienced vomiting
during pregnancy, independently of whether or not they also experienced nausea. Birth weight is presented both unadjusted and adjusted for pre-pregnancy maternal
BMI, gestational age at birth, parity, multi-fetal pregnancy and sex. LBW OR was adjusted for parity, marital status, ethnicity and maternal smoking status. Data are mean
(95% CI) or number (%)
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encompass them both. Nausea and vomiting in preg-
nancy are thought to be protective towards the embryo/
fetus in terms of reducing exposure to food borne harm-
ful substances such as infective microorganisms [43],
and they can lead to changes in the maternal dietary in-
take [44]. There is evidence that this can lead to positive
effects on the fetus such as decreased rates of miscar-
riage and congenital malformations [45]. Whilst poten-
tially being an advantage in a mild form, in excess it is
possible that this vomiting might reduce nutrient deliv-
ery to the fetus leading to the greater risk of LBW [46].
The fact that in our population as a whole there was no
apparent decrease in mean birth weight despite the
higher prevalence of LBW suggests that whilst there is a
negative impact of vomiting on birth weight for some
babies, in other babies a protective advantage may be
evident [43]. The Kernel density estimation plot for birth
weight in our population (Fig. 1(a)) would appear to be
consistent with this suggestion (as birth weight density
around the mean appeared to be higher in those women
affected by vomiting).
LBW often relates to the baby undergoing fetal growth
restriction and/or being born prematurely. Given the in-
crease in birth weight usually observed in male babies,
in general there is also a slightly increased risk of LBW
in female babies compared to males [9]. In our popula-
tion despite the association between vomiting and LBW,
we did not find further significant independent associa-
tions between exposure to vomiting in pregnancy and
the prevalence of SGA (a group that may have been
enriched with babies who underwent fetal growth re-
striction) or premature births or the gestational age at
birth. Looking at the Kernel density estimation plots for
birth weight in our population below the cut off for
LBW the line for women who experienced vomiting was
clearly a little higher than those representing the other
groups (Fig. 1(a)). The differences between the groups
below the cut offs in the gestational ages at birth (to as-
sess the densities related to prematurity) and the birth
weights for gestational age (to assess the densities re-
lated to SGA) plots were smaller though (Fig. 1 (b) and
(c)). Further studies are required to validate these find-
ings in other cohorts, especially those that are better
able to distinguish whether the LBW relates more to
SGA (and therefore probably fetal growth restriction),
prematurity or a mix of the two.
Whilst we could not ascribe the increased risk of LBW to
fetal growth restriction or premature birth we did note a
slight excess of pregnant women carrying female babies.
This excess has previously been observed with hyperemesis
gravidarum [47]. We recently reported that serum GDF-15
concentrations around week 15 of pregnancy were higher
in those women reporting vomiting in the second trimester
of pregnancy in the Cambridge Baby Growth Study [48], a
hormone that may stimulate vomiting in pregnancy [49].
Interestingly we have also observed an increased concentra-
tion of week 15 serum GDF-15 concentrations in women
carrying females compared to those carrying males in our
population (Petry et al., unpublished observation), which
may explain the slight excess of pregnant women carrying
females in the group that experienced vomiting.
The main strengths of this study are its prospective na-
ture and the fact that its design enabled us to study a group
of women with a potentially milder, albeit still unpleasant
phenotype than has been tested in other published studies.
We have therefore uniquely been able to observe that the
risk of giving birth to a LBW baby is higher with vomiting.
The study’s main limitation is that the nausea and vomiting
and the taking of any anti-emetics to treat it were self-
reported. The analysis could therefore have been affected
by recall bias [50], although given that the women were en-
couraged to fill in their questionnaires as their pregnancies
progressed rather than retrospectively the effects of this
may have been limited. Indeed effects of any recall bias
were clearly not sufficient to prevent us from discovering
our association between increased circulating GDF-15 con-
centrations and second trimester vomiting [48]. Another
limitation of our study may be a slight lack of statistical
power to investigate potential effects of confounders. How-
ever there was clearly sufficient power in our study to test
associations between the maternal experience of nausea
and vomiting in pregnancy and the risk of delivering LBW
babies. The final main limitation may be exclusion of
women who took anti-emetics during pregnancy. This is
because the threshold for nausea and vomiting where
women sought and were then prescribed anti-emetics
would have varied from participant to participant, and
therefore the exclusion could have been rather self-
selecting. However the advantage of doing this is the lack
of potential confounding in our study of these drugs affect-
ing pathways involved in regulating fetal growth, a strength
of the study.
(See figure on previous page.)
Fig. 1 Kernel density estimation plots of a unadjusted birth weight distributions, b gestational age at birth and c birth weight adjusted for
gestational age at birth percentiles in the Cambridge Baby Growth Study in babies whose mothers were not treated with anti-emetics in pregnancy.
The lines are plotted according to the mother’s exposure to nausea or vomiting in pregnancy. The cut off for LBW is shown by the dotted line at
2.5 kg in (a), that for prematurity is shown by the dotted line at 37 weeks in (b) and that for SGA is shown by the dotted line at the tenth percentile of
birth weight adjusted for gestational age at birth in (c). Nausea refers to those women who experienced nausea but not vomiting during pregnancy.
Vomiting refers to those women who experienced vomiting during pregnancy, independently of whether or not they also experienced nausea
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Conclusions
This study suggests that vomiting in early pregnancy
of insufficient severity to merit self-selected treatment
with anti-emetics is associated with a higher risk of a
woman giving birth to a LBW baby. It is possible that
this vomiting may therefore be a marker of LBW
pregnancies. This could be useful in situations where
routine ultrasound is not available to distinguish pre-
maturity from being SGA, so LBW is used as an al-
ternative to encompass them both.
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